Additional Safety Considerations With PBC Treatments

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL ,Sandy Sallam, PharmD, BCACP, CDCES

Panelists discuss how managing primary biliary cholangitis (PBC) in women of childbearing age requires careful consideration of pregnancy risk categories for different medications, with UDCA being the safest option during pregnancy, while second-line therapies require strict contraception and careful monitoring of hormone interactions to ensure optimal safety and efficacy.

EP: 1.Presentation and Diagnosis of Primary Biliary Cholangitis

EP: 2.Available Treatment Options for PBC

EP: 3.Treatment Goals for Patients With PBC

EP: 4.Exploring Second-Line Treatments for PBC

EP: 5.Examining Elafibranor as a Treatment Option for PBC

EP: 6.Discussing Seladelpar as a Potential Therapeutic for PBC

EP: 7.Long-Term Considerations for PBC Treatment Options

EP: 8.Safety Considerations When Initiating Treatment for PBC

EP: 9.Analyzing Hepatotoxicity as a Safety Concern With PBC Therapies

Now Viewing

EP: 10.Additional Safety Considerations With PBC Treatments

Video content above is prompted by the following:

How should clinicians approach fetal toxicity risks with PBC treatments, especially when managing women of childbearing age, and what precautions are recommended?
Explain the relevance of the interaction between PBC therapies and hormone replacement therapy. How should these interactions be managed to ensure patient safety?